The system
Moonwalk Biosciences pivots to RNAi obesity drugs with $70M
Moonwalk Biosciences has raised $70 million in Series B funding to advance a pipeline of RNA interference drugs for obesity.
#obesity
Every Medical Research story tagged obesity.
The system
Obesity Medicines Are Disruptive Innovation
A commentary in Nature Medicine argues that new anti-obesity drugs represent a disruptive innovation requiring health system adaptation.